HSCS
HeartSciences Inc.
Last earnings -0.7% on 2026-03-16
$2.95
▼ -1.50%$2.95▼ -19.54%
over 1Y
L $1.67EODHDH $5.73
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-1.5%
1W-1.7%
1M+63.3%
3M+30.7%
YTD-6.4%
1Y-19.7%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 8 analysts
Buy
Revenue fell -76.6% YoY.
Revenue (FY2025) $4.35K · FY2025
HeartSciences Inc. shows $4.35K in FY2025 revenue (-76.6% YoY), a -201499.5% net margin, and -4272.2% ROE.
Financials · annual, by fiscal year
| Line item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | $14.4K | $5.15K | $18.6K | $4.35K |
| Gross profit | $6.48K | $2.35K | $12.5K | $2.47K |
| Operating income | -$4.71M | -$6.11M | -$6.31M | -$8.35M |
| Net income | -$4.83M | -$6.35M | -$6.61M | -$8.77M |
| Diluted EPS | -$1.45 | -$80.00 | -$18.74 | -$9.34 |
| Net margin | -33592.6% | -123384.3% | -35511.9% | -201499.5% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$4.60M
EV / EBITDA—
EV / Sales1057.1
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-153.9%
FCF yield-130.2%
Quality & risk
ROIC (est.)-3216.1%
Free cash flow-$7.42M
Total debt—
Net cash$1.10M
Altman Z-Score-31.35 distress
Piotroski F-Score1/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+126.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Officer / director change2026-06-26
- 8-K Reg FD disclosure2026-06-23
- 8-K Officer / director change2026-06-23
- 8-K Shareholder vote2026-05-06
- 8-K Officer / director change2026-04-03
- DEF 14A Proxy statement2026-03-17
- 8-K Earnings results2026-03-16
- 10-Q Quarterly report2026-03-16
- 10-Q Quarterly report2025-12-15
Recent filings
all on EDGAR ↗DEFA14AFiling2026-06-26open ↗8-KPeriod ending 2026-06-222026-06-26open ↗DEFA14AFiling2026-06-26open ↗DEFA14AFiling2026-06-26open ↗DEFA14AFiling2026-06-25open ↗4Period ending 2026-06-222026-06-24open ↗DEFA14AFiling2026-06-24open ↗SCHEDULE 13GFiling2026-06-24open ↗DEFA14AFiling2026-06-23open ↗8-KPeriod ending 2026-06-232026-06-23open ↗DEFA14AFiling2026-06-23open ↗8-KPeriod ending 2026-06-222026-06-23open ↗
Frequently asked
- Is HeartSciences Inc. (HSCS) a buy?
- HSCS currently carries a Avoid rating with 5/5 conviction, derived from its latest SEC filings. Revenue fell -76.6% YoY.
- What is HeartSciences Inc.'s quality score?
- HSCS scores 25.509803921568626/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001468492, latest 10-Q filed 2026-03-16) · EODHD · as of 6/26/2026, 11:37:57 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.